CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas, and among the top two globally in clinical development. First-in-human study data show that CS5001 is well tolerated with promising anti-tumor activity at various dose levels in heavily pretreated, advanced solid tumors and lymphomas. Dose escalation in the.
Poster presentation highlights strong safety and pharmacokinetic profiles for LNCB74BELTSVILLE, Md., April 08, 2024 NextCure, Inc. , a clinical-stage biopharmaceutical company committed to.